BostonGene
BostonGene is a biotechnology company whose AI-powered platform analyzes genomic and immune data to guide personalized cancer treatment decisions.
Secondary Market Price
How BostonGene Measures Up
To help you manage your BostonGene equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of BostonGene's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future BostonGene Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for BostonGene's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
BostonGene, founded in 2015, is a biomedical software company that applies artificial intelligence to oncology. The company utilizes a platform that integrates omnimodal data—including genomic, transcriptomic, and immune information—with clinical outcomes to assist in cancer patient care and drug development. This technology is used to provide analytics that help clinicians evaluate treatment options and to support biopharmaceutical companies in designing clinical trials, identifying novel targets, and predicting therapeutic responses. Since its establishment, the company has developed its platform through a real-world clinical testing network and has secured funding, including a $150 million Series B round in May 2022.
Recently, BostonGene has formed partnerships with pharmaceutical companies, including a collaboration with AstraZeneca to accelerate oncology development and another with Ottimo Pharma to support the development of a bifunctional therapy. The company has also received industry recognition, including a 2025 Global Technology Innovation Leadership Award from Frost & Sullivan and was named 'Overall Immunology Company of the Year' by BioTech Breakthrough. BostonGene's future plans involve expanding its biopharma collaborations and further integrating its analytical model into clinical and research environments to improve patient selection and optimize therapeutic response prediction.
- NEC Corporation
- Impact Investment Capital
- Japan Industrial Partners
- SoftBank Vision Fund 2
- Eldridge
- Tiger Global Management
- Co-Founder, CEO Brain Schimpf
- Co-Founder, Andrew Feinberg
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is BostonGene worth joining?
Deciding whether to join BostonGene depends on your personal career goals and how you evaluate the company's total compensation package, including its equity. Tools like Prospect can help you forecast the potential value of your equity, providing crucial data for your decision.
What should I do with my BostonGene stock?
Managing your BostonGene stock requires a strategy tailored to your financial goals, as decisions about exercising options or selling shares have significant tax implications. Prospect builds customized equity strategies to help you maximize the value of your shares and minimize your tax burden.
Can you sell BostonGene stock?
As BostonGene is a private company, you can typically only sell stock during specific events like tender offers or on secondary markets, which can be infrequent. When an opportunity to sell arises, Prospect’s Tender Offer Tools can help you determine how much to sell and which shares are the most tax-optimal.
How can I find the value of my BostonGene stock?
The official value of your BostonGene stock is determined by its 409A valuation, but this doesn't reflect its future potential. To get a better forecast, you can use platforms like Prospect, which employ proprietary predictive models to project your equity's future worth based on various data points.
What is BostonGene's equity worth?
The current worth of BostonGene's equity is based on its latest 409A valuation, but its future value depends on the company's growth and eventual exit. Prospect can help you understand this potential by using data-driven models to forecast a range of likely outcomes for your shares.
What is BostonGene's stock ticker symbol?
BostonGene does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. A ticker symbol will only be assigned if the company decides to go public in the future.
Can I buy or sell BostonGene stock?
As an employee, you can "buy" stock by exercising your options, but selling those shares is typically restricted to specific company-approved windows like tender offers. Platforms like Prospect provide personalized strategies for both exercising options and selling shares to optimize your financial outcome.
What is the criteria to buy or invest in BostonGene stock?
Investing in a private company like BostonGene is typically restricted to accredited investors during formal funding rounds or employees who receive equity as compensation. If you are an employee with equity, tools from Prospect are designed to help you manage and maximize the value of your holdings.
